U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06811025) titled 'Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis' on Jan. 31.
Brief Summary: Contezolid is a novel oxazolidinone antibiotic developed by Shanghai Mengke Pharmaceutical Co., Ltd., which successfully went public in 2021. It inhibits bacterial growth by interfering with protein synthesis through its translational inhibitory effect on bacteria. Contezolid has demonstrated promising clinical results in patients with drug-resistant tuberculosis, making it a powerful tool in the fight against drug-resistant tuberculosis.
Currently, there is a lack of pharmacokinetic data on contezolid in patients with centr...